StockWatch
·

HDFC Bank Ltd Q1 FY27 Results

HDFCBANKQ1 FY27 Results
Filing
Result:Good· Market: CrashedBase effectBroad based

Beat/Miss: Inline · Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValueQ4 FY26Q1 FY26
Revenue90.6K Cr3.9%3.7%
Total Income1.3L Cr13.8%0.0%
Expenditure1.0L Cr19.0%5.4%
PBT27.2K Cr0.9%30.4%
Net Profit20.4K Cr0.2%19.3%
OPM34.22%1.47pp7.17pp
NPM15.31%2.10pp2.47pp
EPS12.505.5%41.1%
View full financials

Adjusted PAT growth of ~9.8% (headline +18.4% flattered by last year's HDB OFS gain/floating provision) came with healthy NII growth (+6.7%), stable NIM (~3.26%), improving asset quality (GNPA 1.40%→1.17%, NNPA 0.41%) and strong 15.4% advance growth — solid, above-average for a bank but not a standout given the base-effect-driven headline and inline-vs-street print.

HDFC BANK · Q1 FY27 · THE VERDICT

Strong Profit Growth Masks a Revenue Engine in Reverse

Reported PAT jumped 19.3% year-on-year, but quarter-on-quarter profit came in essentially flat. The deeper story: balance sheet grew 13–14%, revenue only 3.7%, signalling pricing deterioration or asset quality concerns ahead.

24 Jul 2026 · 6 min read
Reported PAT

₹20,383 Cr

+19.3% YoY

PAT QoQ

+0.2%

Essentially flat

Revenue

₹90,575 Cr

+3.7% YoY (vs +13–14% balance sheet)

NIM

34.2% OPM

Compressed, under pressure

On the result screen, HDFC Bank delivered ₹20,383 crore of net profit, up 19.3% year-on-year. That headline masks the quarter's real story: sequential PAT growth of +0.2% is flat, and revenue expanded just 3.7% YoY despite the balance sheet growing 13–14%. The gap between balance sheet momentum and earnings momentum is the question the market is now asking.

The revenue divergence: balance sheet up, earnings flat

Management guided for 'strong advances momentum' and delivered on the loan book: corporate advances up 18%, MSME up 22.3% (with ECLGS 5.0 disbursements of ₹14,000 crore). The balance sheet, however, grew faster than earnings could sustain. Revenue of ₹90,575 crore, up 3.7% YoY, is the weakest part of the print. When the asset base is expanding 13–14% but the top line crawls at 3.7%, the market hears one thing: pricing deterioration, asset quality risk, or both.

Management's claims vs. what holds up

Advances momentum strong, three–four quarters of traction.

Corporate +18% YoY, MSME +22.3%, retail 7–8%. ₹14,000 Cr ECLGS disbursed.

Supported

Cost of funds moderating; margins being managed tactically.

CoF down 40–50 bps YoY but flat QoQ. NIM 34.2% OPM compressed. Borrowing mix 11% (vs industry 5–6%).

Overstated

Deposit growth better than historical Q1; market share gains.

CASA at 34% (target 38–40%). Wholesale deposits rose 17% → 20%. Household growth single-digit, structural.

Partial

PAT growth continues, adjusted 9.8%.

Reported YoY +19.3% strong; QoQ +0.2% (flat). Adjusted 9.8% still lags 13–14% balance sheet growth.

Contradicted on QoQ

Margins bottomed out; stabilization ahead.

Management explicitly avoided QoQ guidance. Structural headwinds (deposits elevated, borrowing mix high) unwind over time, not imminently.

Overstated

What changed on this call

  • Revenue growth deceleration: Prior guidance 'strong advances' → delivered 3.7% YoY. Pricing or mix headwind confirmed.

  • Margin bottoming timeline pushed out: Management now cautious on near-term QoQ; cost-of-funds benefit plays out 'medium-to-long term', not imminent.

  • CASA recovery pace now 2–3 years: Structural household deposit slowdown (RBI-confirmed) driving mix shift. No near-term acceleration.

  • Quality of new advances upgraded: Stricter fraud/mule-account filters in FY24–26 slowing growth, but 'step-up in unit economics' expected as acquisition resumes.

  • Technology & AI roadmap rebalanced: Distribution cap-ex muted; GenAI programs now in production phase. Framed as efficiency lever over 2–3 years, not margin driver.

The bull-bear ledger

  • Advances growth real and diversified (corporate 18%, MSME 22.3%, retail steady).

  • Per-branch productivity best-in-class at ₹330 crore (up from ₹266 Cr FY23).

  • Balance sheet grew 13–14% YoY; the platform expands.

  • Reported PAT +19.3% YoY; YoY comps strong.

  • QoQ PAT +0.2% is flat; momentum broken despite YoY growth.

  • Revenue +3.7% YoY signals pricing deterioration or asset-quality concerns when balance sheet +13–14%.

  • NIM compressed to 34.2% OPM; margin relief not imminent.

  • CASA ratio at 34% vs. target 38%; deposit franchise weakening.

  • Wholesale deposits rising to 20% (from 17%); funding mix deteriorating.

  • Competitive intensity high; corporate spreads thin, deposit rates elevated.

Risks, ranked by how much they should concern a holder

Revenue-to-balance-sheet divergence (balance sheet +13–14%, revenue +3.7%).

High

Signals either asset quality deterioration, pricing erosion, or both. On a ₹24+ trillion asset base, ₹90,575 Cr revenue implies ROA pressure. If unresolved, growth trajectory is broken despite PAT YoY strength.

Margin compression with no near-term relief (NIM 34.2% OPM, borrowing mix 11% vs industry 5–6%).

High

Cost-of-funds benefit 40–50 bps is real but takes 'medium-to-long term' to flow through. Structural headwinds (non-retail deposits elevated, CASA declining) require unwind time. Competitive intensity high; pricing power limited.

CASA ratio decline to 34% (target 38–40%); deposit franchise weakening.

Medium

Household deposit growth structurally low (RBI-confirmed single-digit). Wholesale mix rising (17% → 20%). Recovery hinges on customer acquisition at scale over 2–3 years. If execution falters, CASA may stabilize lower.

QoQ PAT momentum break: +0.2% sequential growth despite +19.3% YoY headline.

Medium

Market interprets QoQ flat as early-stage momentum decay. If next quarter also shows weak sequential growth, the YoY comparison set will roll forward and expose the organic slowdown.

Macroeconomic headwinds: El Niño (Q3 FY27 impact flagged) and West Asia geopolitical risks.

Medium

Agriculture and MSME segments weather-sensitive. Retail credit quality stress possible if rural income impacted. Management noted but offered no hedge specifics.

ECL transition April 2027; stage 2 floors (5% unsecured, etc.) may require enhancement.

Low

Coverage ratio 66% (71% ex-agriculture); management confident. But modeling assumptions on stage 2 defaults carry uncertainty. Provisions may need bolstering if actual delinquencies exceed expectations.

How the street is positioned

The stock closed at ₹747.25 on 23 July 2026, down 26.78% from its all-time high of ₹1020.5. That drawdown reflects a year-long re-rating, not just this quarter. On the day the result was announced (Saturday, 18 July), the stock had closed at ₹819.6. Day 1 brought a -5.12% drop (delivery selling 65.4%); by day 3, the decline had accelerated to -8.11%. The market's verdict: the headline +19.3% PAT growth is not enough to justify the valuation when revenue is creeping at 3.7% and QoQ earnings are flat. The stock now trades below its 20-day (₹800.42), 50-day (₹778.99), and 200-day (₹880.23) moving averages—classic confirmation that the trend has turned.

On the ownership front, FII holdings fell 3.14 percentage points quarter-on-quarter to 38.16%, while DII raised their stake by 2.71pp to 34.93%. This pattern—FII trimming, DII accumulating—is typical of risk-off positioning. Global investors are exiting Indian banking on valuation/growth concerns; domestic institutions are taking the other side at lower prices. Promoter holdings remain at zero (long-standing legacy of HDFC Bank's pre-merger structure), so insider flow data is limited. A government-linked pension fund block trade on 24 June at ₹774.65 suggests no insider urgency to support the stock.

The debate

What to watch next

  • 1 · Q2 FY27 revenue and asset quality

    The key question: does revenue growth recover from 3.7%, or does the balance-sheet-to-revenue divergence persist? Monitor loan disbursements vs. book growth in retail (cards, personal loans, mortgages). If disbursements outpace book growth, it signals quality deterioration (early delinquencies, charge-offs not yet recognized). This is the north star for earnings quality.

  • 2 · FCNR (B) mobilization milestones (Jul–Sep 2026)

    Management targets significant market share on the FCNR window but refused to commit a number. Watch for actual mobilization quantum by end-September. If the take-up is modest, it signals that the funding mix won't normalize as fast as hoped, and margin pressure persists longer.

  • 3 · Cost-of-funds trajectory and deposit mix

    CoF is down 40–50 bps YoY but hasn't flowed to NIM due to elevated wholesale deposit costs and 11% borrowing mix. Watch whether CoF continues to fall QoQ and whether the borrowing mix unwinds toward the 8–9% target. If both stall, margin recovery is pushed into FY28+.

HDFC Bank Q1 FY27 is a tale of headline strength masking organic softness. The ₹20,383 crore reported profit and +19.3% YoY growth are real, but the +0.2% QoQ flat print and +3.7% revenue growth (vs. +13–14% balance sheet) are the signals that matter. The market has already re-rated the stock down 26.78% from its all-time high, and the post-result -8.11% decline confirms it read the earnings quality correctly. This is not a cyclical stumble; it is the beginning of a structural adjustment as pricing power erodes, margins compress, and competitive intensity redlines.

Management's path to recovery (FCNR, GenAI efficiency, CASA unit-economics, operating leverage) is sound in principle but measured in years, not quarters. For holders, the prudent stance is Hold and monitor QoQ momentum and asset quality closely. For new money, this is a cautious entry; the margin of safety is low until revenue growth reaccelerates or near-term EPS visibility improves. The single number to track from here is organic PAT—adjusted for one-timers and measured quarter-on-quarter, not annualized YoY comps. If Q2 shows continued flat sequential growth, the narrative of earnings momentum break will crystallize and the stock may test lower.

Informational and educational content only. Not investment advice.

HDFC Bank Ltd (HDFCBANK) Q1 FY27 Results, Transcript & Analysis — StockWatch